Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19

1 V. J. Hall, S. Foulkes, A. Saei, N. Andrews, B. Oguti, A. Charlett, E. Wellington, J. Stowe, N. Gillson, A. Atti, J. Islam, I. Karagiannis, K. Munro, J. Khawam, M. A. Chand, C. S. Brown, M. Ramsay, J. Lopez-Bernal, S. Hopkins, and SIREN study group, COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study, Lancet (London) 397(10286) (2021) 1725–1735; https://doi.org/10.1016/S0140-6736(21)00790-X Search in Google Scholar

2 J. S. Tregoning, K. E. Flight, S. L. Higham, Z. Wang and B. F. Pierce, Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape, Nat. Rev. Immunol. 21(10) (2021) 626–636; https://doi.org/10.1038/s41577-021-00592-1 Search in Google Scholar

3 A. Kazak, S. Hintistan and Ö. Betül, Dünyada ve Türkiye’de COVID-19 aşı geliştirme çalışmaları (COVID-19 vaccine development studies in the world and in Turkey), Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi (J. Celal Bayar Uni. Health Sci. Inst.) 7(4) (2020) 571–575; https://doi.org/10.348087/cbusbed.749009 Search in Google Scholar

4 M. D. Tanrıöver, H. L. Doğanay, M. Akova, H. R. Güner, A. Azap, S. Akhan, Ş. Köse, F. Ş. Erdinç, E. H. Akalın, Ö. F. Tabak, H. Pullukçu, Ö. Batum, S. Ş. Yavuz, Ö. Turhan, M. T. Yıldırmak, İ. Köksal, Y. Taşova, V. Korten, G. Yılmaz, M. K. Çelen, S. Altin, İ. Çelik, Y. Bayındır, İ. Karaoğlan, A. Yılmaz, A. Özkul, H. Gür, S. Unal, and the CoronaVac study group, Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey, Lancet (London) 398(10296) (2021) 213–222; https://doi.org/10.1016/S0140-6736(21)01429-X Search in Google Scholar

5 T. Fiolet, Y. Kherabi, C. J. MacDonald, J. Ghosn and N. Peiffer-Smadja, Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review, Clin. Microb. Infect. 28(2) (2022) 202–221; https://doi.org/10.1016/j.cmi.2021.10.005 Search in Google Scholar

6 M. G. Thompson, J. L. Burgess, A. L. Naleway, H. L. Tyner, S. K. Yoon, J. Meece, L. E. W. Olsho, A. J. Caban-Martinez, A. Fowlkes, K. Lutrick, J. L. Kuntz, K. Dunnigan, M. J. Odean, K. T. Hegmann, E. Stefanski, L. J. Edwards, N. Schaefer-Solle, L. Grant, K. Ellingson, H. C. Groom, T. Zunie, M. S. Thiese, L. Ivacic, M. G. Wesley, J. M. Lamberte, X. Sun, M. E. Smith, A. L. Phillips, K. D. Groover, Y. M. Yoo, J. Gerald, R. T. Brown, M. K. Herring, G. Joseph, S. Beitel, T. C. Morrill, J. Mak, P. Rivers, K. M. Harris, D. R. Hunt, M. L. Arvay, P. Kutty, A. M. Fry, M. Gaglani, Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers – Eight U.S. locations, December 2020-March 2021, Morb. Mortal. Weekly Rep. 70(13) (2021) 495–500; https://doi.org/10.15585/mmwr.mm7013e3 Search in Google Scholar

7 V. Hall, S. Foulkes, F. Insalata, P. Kirwan, A. Saei, A. Atti, E. Wellington, J. Khawam, K. Munro, M. Cole, C. Tranquillini, A. Taylor-Kerr, N. Hettiarachchi, D. Calbraith, N. Sajedi, I. Milligan, Y. Themistocleous, D. Corrigan, L. Cromey, L. Price, S. Stewart, E. de Lacy, C. Norman, E. Linley, A. D. Otter, A. Semper, J. Hewson, S. D’Arcangelo, M. Chand, C. S. Brown, T. Brooks, J. Islam, A. Charlett and S. Hopkins (for the SIREN Study Group), Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection, N. Engl. J. Med. 386 (2022) 1207–1220; https://doi.org/10.1056/NEJMoa2118691 Search in Google Scholar

8 N. Andrews, J. Stowe, F. Kirsebom, S. Toffa, T. Rickeard, E. Gallagher, C. Gower, M. Kall, N. Groves, A.-M. O’Connell, D. Simons, P. B. Blomquist, A. Zaidi, S. Nash, N. I. B. A. Aziz, S. Thelwall, G. Dabrera, R. Myers, G. Amirthalingam, S. Gharbia, J. C. Barrett, R. Elson, S. N. Ladhani, N. Ferguson, M. Zambon, C. N. J. Campbell, K. Brown, S. Hopkins, M. Chand, M. Ramsay and J. Lopez Bernal, Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant, New Engl. J. Med. 386(16) (2022) 1532–1546; https://doi.org/10.1056/NEJMoa2119451 Search in Google Scholar

9 European Centre for Disease Prevention and Control, Implications of the Further Emergence and Spread of the SARS CoV-2 B.1.1.529 Variant of Concern (Omicron) for the EU/EEA – first update, December 2, 2021; https://www.ecdc.europa.eu/sites/default/files/documents/threat-assessment-covid-19-emergence-sars-cov-2-variant-omicron-december-2021.pdf; last access data March 3, 2023. Search in Google Scholar

10 R. R. Goel, M. M. Painter, S. A. Apostolidis, D. Mathew, W. Meng, A. M. Rosenfeld, K. A. Lund-green, A. Reynaldi, D. S. Khoury, A. Pattekar, S. Gouma, L. Kuri-Cervantes, P. Hicks, S. Dysinger, A. Hicks, H. Sharma, S. Herring, S. Korte, A. E. Baxter, D. A. Oldridge, J. R. Giles, M. E. Weirick, C. M. McAllister, M. Awofolaju, N. Tanenbaum, E. M. Drapeau, J. Dougherty, S. Long, K. D’Andrea, J. T. Hamilton, M. McLaughlin, J. C. Williams, S. Adamski, O. Kuthuru, U. Penn COVID Processing Unit; I. Frank, M. R. Betts, L. A. Vella, A. Grifoni, D. Weiskopf, A. Sette, S. E. Hensley, M. P. Davenport, P. Bates, E. T. Luning Prak, A. R. Greenplate and E. J. Wherry, mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern, Science (New York) 374(6572) (2021) Article ID 1214 (17 pages); https://doi.org/10.1126/science.abm0829 Search in Google Scholar

11 Y. M. Bar-On, Y. Goldberg, M. Mandel, O. Bodenheimer, L. Freedman, N. Kalkstein, B. Mizrahi, S. Alroy-Preis, N. Ash, R. Milo and A. Huppert, Protection of BNT162b2 vaccine booster against Covid-19 in Israel, New Engl. J. Med. 385(15) (2021) 1393–1400; https://doi.org/10.1056/NEJMoa2114255 Search in Google Scholar

12 D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao, S. J. Kent, J. A. Triccas and M. P. Davenport, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat. Med. 27(7) (2021) 1205–1211; https://doi.org/10.1038/s41591-021-01377-8 Search in Google Scholar

13 World Health Organization, WHO COVID-19 Case Definition – Updated in Public health surveil-lance for COVID-19, WHO, 22 July 2022; https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020; last access date March 3, 2023. Search in Google Scholar

14 Republic of Turkey – Ministry of Health, Covid-19 Vaccine Information Platform, Covid-19 Aşısı Ulusal Uygulama Stratejisi (Covid-19 Vaccine National Implementation Strategy); https://covid19asi.saglik.gov.tr/TR-77706/covid-19-asisi-ulusal-uygulama-stratejisi.html Search in Google Scholar

15 C. K. P. Mok, C. A. Cohen, S. M. S. Cheng, C. Chen, K. O. Kwok, K. Yiu, T. O. Chan, M. Bull, K. C. Ling, Z. Dai, S. S. Ng, G. C. Lui, C. Wu, G. K. Amarasinghe, D. W. Leung, S. Y. S. Wong, S. A. Valkenburg, M. Peiris and D. S. Hui, Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong, Respirology (Carlton, Vic.) 27(4) (2022) 301–310; https://doi.org/10.1111/resp.14191 Search in Google Scholar

16 F. Rammauro, F. Carrión, N. Olivero-Deibe, M. Fló, A. Ferreira, O. Pritsch and S. Bianchi, Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2, Vaccine 40(35) (2022) 5189–5196; https://doi.org/10.1016/j.vaccine.2022.07.023 Search in Google Scholar

17 W. W. Lim, L. Mak, G. M. Leung, B. J. Cowling and M. Peiris, Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19, Lancet Microbe 2(9) (2021) e423; https://doi.org/10.1016/S2666-5247(21)00177-4 Search in Google Scholar

18 Y. E. Kim, K. Huh, Y. J. Park, K. R. Peck and J. Jung, Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection, JAMA 328(9) (2022) 887–889; https://doi.org/10.1001/jama.2022.12992 Search in Google Scholar

19 J. Xie, Z. Tong, X. Guan, B. Du, H. Qiu and A. S. Slutsky, Critical care crisis and some recommendations during the COVID-19 epidemic in China, Int. Care Med. 46(5) (2020) 837–840; https://doi.org/10.1007/s00134-020-05979-7 Search in Google Scholar

20 B. Sandalc, O. A. Uyaroğlu and G. S. Güven, COVID-19’da kronik hastalıkların rolü, önemi ve öneriler (The role and importance of chronic diseases in COVID-19 and related recommendations), Flora 25(2) (2020) 132–138; https://doi.org/10.5578/flora.69700 Search in Google Scholar

21 Y. Zou, D. Huang, Q. Jiang, Y. Guo and C. Chen, The vaccine efficacy against the SARS-CoV-2 Omicron: A systemic review and meta-analysis, Front. Public Health 10 (2022) Article ID 940956 (9 pages); https://doi.org/10.3389/fpubh.2022.940956 Search in Google Scholar

22 L. Wang, M. H. Kainulainen, N. Jiang, H. Di, G. Bonenfant, L. Mills, M. Currier, P. Shrivastava-Ranjan, B. M. Calderon, M. Sheth, B. R. Mann, J. Hossain, X. Lin, S. Lester, E. A. Pusch, J. Jones, D. Cui, P. Chatterjee, M. H. Jenks, E. K. Morantz, G. P. Larson, M. Hatta, J. L. Harcourt, A. Tamin, Y. Li, Y. Tao, K. Zhao, K. Lacek, A. Burroughs, W. Wang, M. Wilson, T. Wong, S. H. Park, S. Tong, J. R. Barnes, M. W. Tenforde, W. H. Self, N. I. Shapiro, M. C. Exline, D. C. Files, K. W. Gibbs, D. N. Hager, M. Patel, A. L. Halpin, L. K. McMullan, J. S. Lee, H. Xia, X. Xie, P.-Y. Shi, C. T. Davis, C. F. Spiropoulou, N. J. Thornburg, M. S. Oberste, V. G. Dugan, SSEV Bioinformatics Working Group, D. E. Wentworth and B. Zhou, Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines, Nature Commun. 13(1) (2022) Article ID 4350 (10 pages); https://doi.org/10.1038/s41467-022-31929-6 Search in Google Scholar

23 M. J. Cohen, Y. Oster, A. E. Moses, A. Spitzer, S. Benenson and Israeli-Hospitals 4th Vaccine Working Group, Association of receiving a fourth dose of the BNT162b vaccine with SARS-CoV-2 infection among health care workers in Israel, JAMA Network Open 5(8) (2022) e2224657 (7 pages); https://doi.org/10.1001/jamanetworkopen.2022.24657 Search in Google Scholar

24 V. K. C. Yan, E. Y. F. Wan, X. Ye, A. H. Y. Mok, F. T. T. Lai, C. S. L. Chui, X. Li, C. K. H. Wong, P. H. Li, T. Ma, S. Qin, V. K. C. Wong, T. C. Tsang, S. H. Tsui, W. C. M. Chui, B. J. Cowling, G. M. Leung, C. S. Lau, I. C. K. Wong and E. W. Y. Chan, Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study, Emerg. Microbes Infect. 11(1) (2022) 2304–2314; https://doi.org/10.1080/22221751.2022.2 114854 Search in Google Scholar